Home>News>The Value of MIPI and Ki-67 in Mantle Cell Lymphoma
The Value of MIPI and Ki-67 in Mantle Cell Lymphoma
Thursday, December 28, 2017
John P. Leonard, M.D., interim chair of the Department of Medicine, associate dean of clinical research, Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, professor of medicine, hosts a panel discussion on the topic of Mantle Cell Lymphoma International Prognostic Index. The Index evaluates four components (age, leukocytosis, lactate dehydrogenase, and performance status) under three categories: high risk, intermediate risk, and low risk.